Showing 23,074 news articles about PEP

Filters Content type: Editors' picks Topic: PEP

Post-exposure prophylaxis involves taking a 28-day course of anti-HIV drugs, after possible exposure to HIV. It may be used by healthcare workers (occupational PEP) or after sex (post-exposure prophylaxis after sexual exposure, PEPSE, also known as non-occupational PEP or nPEP).

New & experimental hepatitis C treatment

England: Patients with end-stage liver disease caused by hepatitis C to get new drug

Editor's pick
The Guardian
17 April 2014
Hepatitis C treatment

WHO issues its first hepatitis C treatment guidelines

Editor's pick
World Health Organization
9 April 2014
Hepatitis C symptoms & diagnosis

WHO Hepatitis Treatment Guidelines: UNITAID Urges Efforts to Improve Diagnosis as Key to Increase Access to Medicines

Editor's pick
UNITAID
9 April 2014
Access to healthcare

Gilead aims to license hepatitis C drug to 3-4 Indian firms

Editor's pick
Reuters
9 April 2014
Hepatitis C treatment

Gilead says has discounted hepatitis C drug for some health plans

Editor's pick
Reuters
31 March 2014
Hepatitis C transmission & prevention

Eliminating hepatitis C – an ambitious but achievable goal

Editor's pick
The Conversation
28 March 2014
Hepatitis C treatment

Should Prisoners Get Expensive Hepatitis C Drugs?

Editor's pick
Stateline
25 March 2014
Hepatitis C treatment

Hepatitis C treatments: Australia urged to subsidise 'revolutionary' new drugs

Editor's pick
ABC Online
18 March 2014
Hepatitis C treatment

Merck hepatitis C drugs work in HIV co-infected patients -study

Editor's pick
Reuters
5 March 2014
Hepatitis C treatment

Fewer Americans are living with hepatitis C, because more have died

Editor's pick
Los Angeles Times
4 March 2014
Hepatitis C treatment

Could new hepatitis C drugs bust state budgets?

Editor's pick
USA Today
4 March 2014
Bad science & bogus treatments

Egypt claims miracle cure for HIV and Hepatitis

Editor's pick
The Commentator
27 February 2014
New & experimental hepatitis C treatment

Gilead's CEO Says New Hepatitis C Drug Attracts Payers

Editor's pick
Bloomberg Businessweek
13 February 2014
New & experimental hepatitis C treatment

New hepatitis C pill lifts Gilead's 4Q sales

Editor's pick
Bloomberg Businessweek
7 February 2014
Access to healthcare

At $84000 Gilead Hepatitis C Drug Sets Off Payer Revolt

Editor's pick
Bloomberg
27 January 2014
Hepatitis C transmission & prevention

Prevalence of hepatitis C infection found to vary widely among Hispanics

Editor's pick
Medical Xpress
14 January 2014
New & experimental hepatitis C treatment

$1000 Pill For Hepatitis C Spurs Debate Over Drug Prices

Editor's pick
NPR (blog)
6 January 2014
Hepatitis C treatment

Gilead Sciences, Inc. (GILD): Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014

Editor's pick
Seeking Alpha
3 January 2014
Hepatitis C transmission & prevention

Patient catches hepatitis C in Edinburgh hospital

Editor's pick
The Scotsman
30 December 2013
New & experimental hepatitis C treatment

Stellar hepatitis C data puts Gilead farther ahead of pack

Editor's pick
Reuters
24 December 2013
Access to healthcare

Egyptians hold their breath as new Hepatitis C drugs promise cure

Editor's pick
Ahram Online
24 December 2013
New & experimental hepatitis C treatment

Analysis: Fight for cheap drugs shifts from AIDS to new hepatitis pills

Editor's pick
Reuters
16 December 2013
New & experimental hepatitis C treatment

US FDA approves Gilead's $1000-a-day hepatitis C pill

Editor's pick
Reuters
8 December 2013
New & experimental hepatitis C treatment

Sofosbuvir for Hepatitis C: Simpler, Shorter, Safer?

Editor's pick
Medscape (requires registration)
4 December 2013